IL33 and atherosclerosis: Even though Miller et al. [23] demonstrated that the IL-33-ST2L pathway might inhibit the development of atherosclerosis, recent studies revealed the association between IL-33-ST2L pathway and coronary artery disease [24], and the association of soluble ST2 levels with all-causes and cardiovascular mortality [25].